WO1990011768A2 - Method for treating respiratory distress syndrome - Google Patents
Method for treating respiratory distress syndrome Download PDFInfo
- Publication number
- WO1990011768A2 WO1990011768A2 PCT/US1990/001410 US9001410W WO9011768A2 WO 1990011768 A2 WO1990011768 A2 WO 1990011768A2 US 9001410 W US9001410 W US 9001410W WO 9011768 A2 WO9011768 A2 WO 9011768A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- surfactant
- respiratory distress
- distress syndrome
- fetus
- lung
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- This invention relates to the therapy of respiratory distress syndrome.
- it relates to novel methods for the use of lung surfactants in the treatment of respiratory distress.
- Neonatal respiratory distress syndrome also known as hyaline membrane disease
- RDS Neonatal respiratory distress syndrome
- hyaline membrane disease is a major cause of morbidity and mortality of the prematurely born infant. It has been estimated that almost 20% of infants born at 30-32 weeks gestational age and between 60 and 80% of infants born at 26-28 weeks gestational age will develop RDS (Jobe, et al, Am. Rev. Resp. Dis. 136:1256, 1987). RDS currently leads to the death bf approximately 5000 infants annually in the United States (Wegman, Pediatrics 74:981, 1984). Many RDS- af flicted infants will survive, but suffer with major medical complications including chronic lung disease (bronchopulmonary dysplasia) and neurological defects.
- chronic lung disease bronchopulmonary dysplasia
- RDS in the premature infant is believed to be caused primarily by a deficiency of lung surfactant — a lipid-protein mixture which coats the airspaces of the lung — thereby reducing the surface tension and preventing airspace collapse.
- lung surfactant dipalmitoylphosphatidylcholine (DPPC)
- DPPC dipalmitoylphosphatidylcholine
- preparations can be classified into five types. These include 1) natural human surfactant (purified from human amniotic fluid), (Merritt, et al., N. Engl. J. Med.
- prophylactic adminstration of exogenous surfactant i.e., after birth and before the first breath (Enhorning, et al, Pediatrics, 76:145, 1985; Merritt, et al., N. Engl. J. Med., 315:785, 1986).
- surfactant which is administered after birth may not be distributed evenly throughout the lungs.
- surfactant is taken up as an emulsion into a syringe and is administered directly into the lungs of a patient through an endotracheal tube.
- surfactant is typically administered in several aliquots with the patient turned in different positions for each administration.
- Results from animal and human studies suggest that uneven distribution may be a serious problem with the current methods for surfactant administration.
- Robertson and Enhorning administered a suspension of concentrated natural surfactant mixed with iron-dextran to premature rabbits, and observed an uneven distribution (Pediatrics, 50:58, 1972). Uneven distribution has also been suggested by reports of infants who have shown unilateral improvement on their chest radiographs (Fujiwara, supra; Edwards, et al, Radiology 157:329, 1985).
- administration of surfactant to the newborn after birth subjects the infant to many avoidable iatrogenic complications.
- Administration of surfactant after birth typically requires the placement of an endotracheal tube, hand-bagging, and a period of mechanical ventilation using a pressure-regulated respirator. Risks associated with these procedures include, but are not limited to, improper placement of the endotracheal tube, barotrauma secondary to excessive pressures during bagging or mechanical ventilation, lung overdistension and cardiac compromise if lung compliance improves with therapy and the ventilator delivers excessive volumes, as well as the risks of infection, tracheal stenosis, bronchopulmonary dysplasia and even death from mechanical failure (Perelman, supra).
- Intraamniotic administration of an agent comprises the insertion of that agent into the amniotic cavity, typically by a thin needle. This procedure per se is widely known to practitioners, and has been used both for analytical and therapeutic purposes.
- Amniocentesis is the insertion of a needle into the amniotic cavity in order to remove a small amount of amniotic fluid for analysis.
- the combined use of ultrasonography and a thin needle have made amniocentesis remarkably safe for both the mother and the fetus (Picker et al., Aust. N. Z. J. Obstet. Gynec. 19:83, 1979).
- Amniocentesis is commonly performed in preterm labor to assess fetal lung maturity and to determine the risk of RDS.
- Insertion of a needle into the amniotic cavity for treatment purposes has been shown to be a convenient and effective method for delivering therapeutic agents.
- the most common approach has been to insert a needle through the abdominal wall of the mother into the amniotic cavity.
- hypertonic saline and prostaglandins have been injected in order to induce therapeutic abortions (Bygdeman,
- thyroid hormone has been injected in order to induce lung maturity in the fetus (Mashiach, et al., J. Perinat. Med. 7:161, 1979), and bicarbonate has been injected to treat fetal acidosis (Hamilton, et al., Am. J. Obstet. Gynecol. 112:834,
- antibiotics have been administered into the amniotic cavity after premature rupture of the membranes by insertion of a needle through the cervical canal
- Transamniotic administration comprises the delivery of a therapeutic agent directly to the fetus.
- This .procedure per se is also widely known to practitioners. It has been used, for example, for intrauterine fetal blood transfusion therapy by injection into the fetal peritoneal cavity (Birnholz, et al., N. Engl. J. Med. 304:1021, 1981).
- transamniotic administration of a drug directly into the lungs of a fetus by "fetobronchoscopy" has not been described.
- the objects of this invention are accomplished by a method comprising treating a patient at risk for respiratory distress syndrome by the fetal delivery of a therapeutically effective dose of lung surfactant. In one embodiment, this is accomplished through intraamniotic administration before delivery. This method ensures that the surfactant is evenly distributed throughout the lungs before the first breath. In another embodiment, transamniotic administration delivers surfactant directly to fetal lungs. The administration may desirably be timed so that breathing efforts in utero which are present as early as about
- Surfactant as defined herein means any composition, including lipids and/or proteins, which is capable of lowering the surface tension at air-liquid interfaces in the lung.
- This definition encompasses lung surfactant, as described above, together with its amino acid, glycosylation and other variants or derivatives.
- the literature discussed supra describes suitable lung surfactant preparations. It is expected that other surfactant variants and derivatives will become available in the future, and these are to be considered to fall within the scope of this invention.
- Surfactant is prepared by known methods from synthetic dipalmitoylphosphatidylcholine (DPPC), egg or synthetic phosphatidylglycerol (PG), and purified surfactant apoproteins (SP-B and/or SP-C and/or SP-A). Purified surfactant apoproteins are obtained by recombinant methods or direct synthesis using published nucleotide and amino acid sequences (Glasser, et al., Proc. Natl. Acad. Sci. U.S.A. 84:4007, 1987; Jacobs, et al., J. Biol. Chem. 262:9808, 1987; Floros, et al, J. Biol. Chem.
- surfactant apoproteins are reconstituted with surfactant lipids, Revak, supra.
- Purified surfactant apoproteins may also be obtained from amniotic fluid, human or animal, or from cell culture, using cells which naturally produce these molecules.
- Surfactant is also obtained by isolation of natural surfactant from human or animal amniotic fluid.
- surfactant may be isolated by known methods ⁇ e.g. by organic extraction of lung tissue or by lavage from human or animal lung, and then supplemented with phospholipids, as desired.
- Protein-free synthetic surfactant (Morley, supra; Durand, supra) and any other composition capable of lowering surface tension at the air-liquid interface in the lungs (e.g. Mclver, et al., Biochm. Biophys. Acta 751:74, 1983) are encompassed within the scope of this invention.
- Surfactant from other animal species can be used in the treatment of human respiratory distress syndrome, and vice versa.
- Surfactant for fetal delivery is placed into sterile, isotonic formulations together with required cofactors.
- the formulation of surfactant is preferably liquid, and is ordinarily a physiologic salt solution containing 0.5 - 10 mM calcium, non-phosphate buffer at pH 6.8- 7.6. Saline is a suitable carrier, although other conventional parenteral solutions or buffers are usable.
- the final concentration of surfactant in solution is typically about 10-40 mg/ml, in generally about 0.5 - 30 ml.
- Surfactant may be provided as lyophilized powder for ultimate delivery in solution, or the powder may be encapsulated and inserted into the amniotic cavity through the cervix or by surgical means.
- Surfactant can be administered from sustained release compositions, for example as polylactide or polyhydroxylbutyrate implants or liposomes such as are described in EP 17,2007A, or by continuous infusion.
- Surfactant also is suitably formulated with other pharmacologic agents in order to modify or enhance the half -life, the distribution, or the therapeutic activity of the surfactant.
- These pharmacologic agents may be administered separately to the mother, reaching the fetus via the placenta, or may be coadministered intraamniotically or transamniotically.
- Agents which increase the fetal inspiration of amniotic fluid are suitable for coadministration; for example, maternal administration of glucose has been shown to increase fetal breathing activity (Lewis, et al., Br. J. Obstet. Gynecol. 85:86, 1978).
- Drugs which increase fetal breathing activity or reduce laryngeal contraction and obstruction of the tracheal inlet such as catecholamines may be coadministered (Murata, et al., Am. J. Obstet. Gynecol. 139:942, 1981).
- drugs which reduce the production of fetal pulmonary fluid may facilitate distribution of lung surfactant into the fetal lungs.
- arginine vasopressin and arginine vasotocin and catecholamines suppress tracheal secretion (Perks, et al., Chest 81:63, 1982; Ross, et al., Am. J. Obstet. Gynecol.
- Additional pharmacologic agents suitable for coadministration include those which alter fetal swallowing and may improve distribution of lung surfactant into the lung and/or prolong its half-life.
- the surfactant formulations may contain agents such as unsaturated or saturated fatty acids, and triglycerides previously suggested for use in surfactant dosage forms (Tanaka, et al., Chem. Pharm. Bull. 31:4100, 1983).
- Surfactant optionally is administered together with other agents or therapies heretofore employed in the therapy of respiratory distress syndrome.
- Therapies or agents which are used optionally in a course of therapy with fetal delivery of surfactant include, for example, an interferon (including gamma interferon), corticosteroids, thyroid hormone, tocolytics, relaxin, male and female sex hormones, prolactin, insulin, insulin-like growth factor- 1 , and growth and/or differentiation factors which could induce differentiation of type II cells in fetal lungs and/or increase their surfactant production, such as epithelial growth factor, transforming growth factor beta, or colony stimulating factors. See, for example, Whitsett, et al., J. Biol. Chem.
- agents include vitamin E, superoxide dismutase, alpha- 1-antitrypsin and other an tipro teases, selenium, vitamin A, antibiotics, immunoglobulins, and antiviral agents. These other agents or therapies are used at the same time as surfactant is administered or in a sequential course of therapy.
- surfactant is formulated by a modification of the method of Revak, supra. Briefly, surfactant apoproteins (SP-B and/or SP-C, alone or in combination with SP-A, dissolved in chloroform) and phospholipid (in chloroform) are combined. The mixture is vortexed and dried, and resuspended in a suitable carrier solution, such as 150 mM saline with 1.5 mM CaCl 2 . The final ratio of protein to lipid desirably ranges from 1:99 to 15:85.
- a suitable carrier solution such as 150 mM saline with 1.5 mM CaCl 2 .
- the therapeutically effective dosage of surfactant to be employed by fetal delivery generally will range about from about 5-900 mg per administration, although the dose of the surfactant employed will be dependent upon the properties of the surfactant employed, e.g. its activity and biological half-life, the concentration of the surfactant in the formulation, the rate of dosage, the clinical tolerance of the patients involved, the pathological condition of the patients and the like, as is well within the skill of the physician. It will be appreciated that the practitioner will adjust the therapeutic dose in line with clinical experience for any given surfactant.
- Fetal surfactant administration desirably is used after the measurement of lung surfactant in amniotic fluid reveals a deficiency, or it is used on a prophylactic basis where labor has begun prematurely.
- surfactant is administered to a fetus between about 20 and 44 weeks of gestation.
- Additional doses of surfactant may be administered, before and/or after delivery. Since the half- life of other proteins in amniotic fluid is approximately 24 hours (Gitlin, et al., Am. J. Obstet. Gynecol. 113:632, 1972), additional doses may be given every 12 to 48 hours, before and/or after delivery, unless a sustained-release formulation is employed.
- Surfactant may be delivered to the lungs of the fetus transamniotically as shown in Example 2 below, and/or to an infant after birth by conventional direct installation after placement of an endotracheal tube.
- Surfactant may be delivered after birth by aerosol, using alternatively a dry power aerosol, a liquid aerosol generated by ultrasonic or jet nebulization, or a metered dose inhaler, again avoiding the complications of endotracheal tube placement.
- a woman who enters labor prematurely is admitted, monitored, and given therapeutic agents to diminish uterine contractions.
- An evaluation of fetal age and maturity is performed.
- sonography is used to determine the gestational age and to locate the placenta and an appropriate puncture site.
- the abdomen is prepped with antiseptic solution.
- a 20- or 22-gauge spinal needle 3 to 6 inches long, is inserted into the amniotic cavity under ultrasonic guidance.
- the stylette is removed and the first 1 to 2 ml of amniotic fluid is discarded. A small amount of fluid is removed for analysis.
- the surfactant solution (prepared from synthetic DPPC, egg phosphatidylglycerol (PG) and apoprotein SP-C, as described above) is administered by syringe injection over 1 - 5 minutes.
- the surfactant solution is rapidly injected in order to obtain more rapid distribution.
- a dose of 20 - 900 mg is administered.
- the mother may be asked to move into different positions in order to obtain more rapid distribution of surfactant throughout the amniotic fluid.
- surfactant may be readministered into the amniotic cavity.
- EXAMPLE 2 A woman who enters labor prematurely is admitted, monitored, and if indicated, given therapeutic agents to diminish uterine contractions. An evaluation of fetal age and maturity is prepared. Within the scope of normal obstetrical practice amniocentesis is performed under ultrasonic guidance. A small amount of amniotic fluid is removed and analyzed. If delivery is imminent, or if there has been premature rupture of the membranes and loss of amniotic fluid, it may not be preferable to administer surfactant into the amniotic fluid.
- a "fetobronchoscope” an instrument such as a thin flexible fiberbronchoscope (or chip bronchoscope) is sterilized and then introduced by a percutaneous transabdominal technique, under local anesthesia and with ultrasound guidance (Hobbins, et al., Am. J. Obstet. Gynecol. 118:1069, 1974).
- the endoscope may be introduced into the amniotic cavity by exposing the uterus by laparotomy and inserting the instrument through the myometrial incision.
- the endoscope is then maneuvered into the oral cavity of the fetus, through the larynx, and into the trachea. At that point, lung surfactant is instilled directly into the lungs of the fetus. A dose of 5- 300 mg is administered. Depending on the course of labor, surfactant may be readministered. Additional surfactant may be administered to the lungs of the infant after delivery.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33155689A | 1989-03-31 | 1989-03-31 | |
US331,556 | 1989-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990011768A2 true WO1990011768A2 (en) | 1990-10-18 |
Family
ID=23294451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/001410 WO1990011768A2 (en) | 1989-03-31 | 1990-03-12 | Method for treating respiratory distress syndrome |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0485384A1 (en) |
JP (1) | JPH04504255A (en) |
CA (1) | CA2049301A1 (en) |
WO (1) | WO1990011768A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5683982A (en) * | 1991-11-04 | 1997-11-04 | Merrell Pharmaceuticals Inc. | Synthetic lung surfactant having antioxidant properties |
EP1426057A1 (en) * | 2002-12-04 | 2004-06-09 | Maquet Critical Care AB | Method of preparation of a medicament and a medical device |
US10682396B2 (en) | 2015-06-09 | 2020-06-16 | B.G. Negev Technologies And Applications Ltd | Controlled release system for pulmonary delivery of surfactant protein D |
-
1990
- 1990-03-12 JP JP2505252A patent/JPH04504255A/en active Pending
- 1990-03-12 EP EP90905291A patent/EP0485384A1/en not_active Ceased
- 1990-03-12 CA CA002049301A patent/CA2049301A1/en not_active Abandoned
- 1990-03-12 WO PCT/US1990/001410 patent/WO1990011768A2/en not_active Application Discontinuation
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5683982A (en) * | 1991-11-04 | 1997-11-04 | Merrell Pharmaceuticals Inc. | Synthetic lung surfactant having antioxidant properties |
EP1426057A1 (en) * | 2002-12-04 | 2004-06-09 | Maquet Critical Care AB | Method of preparation of a medicament and a medical device |
US7266403B2 (en) | 2002-12-04 | 2007-09-04 | Maquet Critical Care Ab | Method and device for treating a protein deficiency |
US10682396B2 (en) | 2015-06-09 | 2020-06-16 | B.G. Negev Technologies And Applications Ltd | Controlled release system for pulmonary delivery of surfactant protein D |
Also Published As
Publication number | Publication date |
---|---|
CA2049301A1 (en) | 1990-10-01 |
EP0485384A1 (en) | 1992-05-20 |
JPH04504255A (en) | 1992-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wilkinson et al. | Two controlled trials of dry artificial surfactant: early effects and later outcome in babies with surfactant deficiency | |
JP5490683B2 (en) | Administration method of pulmonary surfactant | |
Gregory | Anesthesia for premature infants | |
US20220040239A1 (en) | Therapeutic combination comprising a pulmonary surfactant and a steroid for the treatment of evolving bpd | |
Galan et al. | Surfactant replacement therapy in utero for prevention of hyaline membrane disease in the preterm baboon | |
Suske et al. | Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant‐substituted preterm infants | |
RU2533450C9 (en) | Therapeutic combination containing lung surfactant and steroid | |
WO1990011768A2 (en) | Method for treating respiratory distress syndrome | |
Rendas et al. | Prematurity, hypoplasia of the pulmonary vascular bed, and hypertension: fatal outcome in a ten-month-old infant | |
KR101784651B1 (en) | Synthetic Pulmonary Surfactant Composition Comprising Analogues of Surfactant Protein B and Surfactant Protein C | |
Ullah | Surfactant therapy in meconium aspiration syndrome (MAS) | |
Thorkildsen | The utilization of exogenous surfactant in the neonate | |
Sumaiya | Temporal Relationship between Surfactant Therapy and Outcome in Respiratory Distress Syndrome in Preterm Neonates | |
BR112020021342A2 (en) | A THERAPEUTIC COMBINATION UNDERSTANDING A LUNG SURFACTANT AND A STEROID FOR PROPHYLAXIS IN DBP | |
LI | Neonatal respiratory distress syndrome: review on current understanding and the new concept | |
Anwar et al. | Section Review: Prevention and treatment of respiratory distress syndrome: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990905291 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2049301 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1990905291 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1990905291 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990905291 Country of ref document: EP |